ClinicalTrials.gg
Not yet recruitingNCT06898060Updated Mar 27, 2025

To Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of Fracture

A Phase 3 interventional study of QLG2128 and Teriparatide Injection in Postmenopausal Women With Osteoporosis, sponsored by Qilu Pharmaceutical Co., Ltd.. Not yet recruiting. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-03-27.

Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
282
Allocation
Randomized
Ages
50 Years to 85 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the efficacy and safety of QLG2128 in the treatment of postmenopausal women with osteoporosis and at high risk of fracture.

02

Conditions studied

  • Postmenopausal Women With Osteoporosis

Browse trials for

03

In context

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.

This study's planned enrollment of 282 is above the median of 88 across 1,084 interventional studies indexed under Osteoporosis.

Browse Osteoporosis studies →

Lead sponsor

Qilu Pharmaceutical Co., Ltd. is the lead sponsor of 200 studies on the registry; 122 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women who can walk freely (≥50 and ≤85 years);
  • The patient has a (BMI) of 17.0 kg/m2 to 30 kg/m2;
  • The patient has a bone mineral density T-score≤-2.5 and > -5.0 at the lumbar spine (L1-L4) or femoral neck or total hip by dual energy x-ray absorptiometry (DXA);
  • The patient has at least one of the following high risk factors of fracture: 1) history of previous fragility fractures; 2) family history of hip fragility fracture; 3) age≥70 years; 4) BMI≤19.0 kg/m2;5) Currently smoking.
  • The patient with at least 2 consecutive vertebrae(L1 to L4) and at least 1 hip can be evaluated for BMD.

Exclusion criteria

Exclusion Criteria:

  • In addition to osteoporosis, the other diseases affecting bone metabolism;
  • History of osteosarcoma;
  • History of orthostatic hypotension;
  • Currently suffering from active urinary calculus;
  • Received anti-osteoporosis treatment that does not meet protocol requirements;
  • Received medication that affects bone metabolism within 4 weeks prior to screening, or is planned to use prohibited drugs/non-drug therapy under the protocol during the study period.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
282 participants (estimated)

Study arms

  • Experimental
    QLG2128

    Drug: QLG2128

  • Active comparator
    Teriparatide Injection

    Drug: Teriparatide Injection

Interventions

  • DrugQLG2128

    Recommended dosage is 80 μg subcutaneously once daily,52week

  • DrugTeriparatideStudies of TeriparatideTeriparatide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Recommended dosage is 20μg subcutaneously once daily,52week

06

What researchers measure

Primary outcomes

  1. Percent Change in Bone Mineral Density (BMD) of Lumbar Spine From Baseline to 52 Week

    Percent Change in Bone Mineral Density (BMD) of Lumbar Spine From Baseline to 52 Week

    Time frame: Baseline to 52 Week

Secondary outcomes

  1. Percent Change in Bone Mineral Density (BMD) of Lumbar Spine From Baseline to 26 Week

    Percent Change in Bone Mineral Density (BMD) of Lumbar Spine From Baseline to 26 Week

    Time frame: Baseline to 26 Week

  2. Percent Change in Bone Mineral Density (BMD) of Total Hip, Femoral Neck From Baseline to 26/52 Week

    Percent Change in Bone Mineral Density (BMD) of Total Hip, Femoral Neck From Baseline to 26/52 Week

    Time frame: Baseline to 26/52 Week

  3. Proportion of Subjects With New Fragility Fractures From Baseline to 26/52 Week

    Proportion of Subjects With New Fragility Fractures From Baseline to 26/52 Week

    Time frame: Baseline to 26/52 Week

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2025; primary completion for May 2027, 23 months later.

Of 35 industry-sponsored phase 3 interventional studies under Osteoporosis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 46. This study's planned 23 months is close to that.

Counting every sponsor, half of 45 studies reached it within 37 months; a quarter within 21 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2025
First posted
Mar 27, 2025
StartEst.
Jun 2025
Primary completionEst.
May 2027
CompletionEst.
May 2027
Last update
Mar 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06898060
Responsible party
Sponsor
First posted
Mar 27, 2025
Start date
Jun 2025 (estimated)
Primary completion
May 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Mar 27, 2025

Study contacts

zhenlin Zhang, Doctor
Contact
zzl2002@medmail.com
13621673716

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion